Platelet Aggregation During the Shift From Clopidogrel to Ticagrelor
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Antiplatelet therapy with ticagrelor is currently indicated for treatment of patients
presenting with acute coronary syndrome. Such therapy is started with the administration of a
loading dose in patients which are not yet under treatment with P2Y12 inhibitors
(antiplatelet agents). However it is unknown whether a loading dose is needed to maintain a
satisfactory inhibition of platelet aggregation in patients who are already treated with a
previous generation P2Y12 inhibitor (clopidogrel) during the passage to the newer compound
ticagrelor. For this reason aim of the present study is to evaluate the levels of platelet
aggregation during the pharmacological shift from clopidogrel to ticagrelor performed with or
without a loading starting dose of the newer drug.